For example, in February 2021, data from the RECOVERY collaboration group controlled clinical trial (NCT04381936) showed that patients who were hospitalized with COVID-19, who were receiving either invasive mechanical ventilation or oxygen and treated with dexamethasone, had a significantly reduced 28-day mortality when compared with patients given usual care [8]

For example, in February 2021, data from the RECOVERY collaboration group controlled clinical trial (NCT04381936) showed that patients who were hospitalized with COVID-19, who were receiving either invasive mechanical ventilation or oxygen and treated with dexamethasone, had a significantly reduced 28-day mortality when compared with patients given usual care [8]. COVID-19. This Editorial aims to present the background to the recent authorization of tocilizumab, a humanized therapeutic monoclonal antibody to the IL-6 receptor (IL-6R), for hospitalized patients with moderate and severe COVID-19 and future Zonampanel combination therapies. Keywords:Editorial; IL6 Protein, Human; IL6R Protein, Human; Tocilizumab; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19 There is no cure for acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Prevention or Zonampanel amelioration of coronavirus disease 2019 (COVID-19) depends on the efficacy of vaccines [1,2]. However, no vaccine is 100% effective. Vaccinated, non-vaccinated, and immunosuppressed individuals will continue to be infected with SARS-CoV-2. Therefore, there is a priority to develop treatments that reduce the severity of COVID-19 in patients who require hospital admission. The US National Institutes of Health (NIH) identifies severe COVID-19 in patients with the following criteria: an oxygen saturation (SpO2) <94% at sea level on room air; a respiratory rate of >30 breaths/min; a ratio of the arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) of <300 mmHg; or pulmonary parenchymal infiltrates of >50% on lung computed tomography (CT) imaging [3]. For more than a year, clinical trials on potential therapeutic approaches to reduce patient mortality from moderate to severe COVID-19 in hospitalized patients Zonampanel have shown varied success compared to supportive care [4,5]. In 2021, there have been promising results for therapeutic approaches that reduce the local and systemic immunological and inflammatory effects of SARS-CoV-2 infection in hospitalized patients with moderate to severe COVID-19. For example, in February 2021, data from the RECOVERY collaboration group controlled clinical trial (NCT04381936) showed that patients who were hospitalized with COVID-19, who were receiving either invasive mechanical ventilation or oxygen and treated with dexamethasone, had a significantly reduced 28-day mortality when compared with patients given usual care [8]. Dexamethasone reduces systemic inflammation, or the cytokine storm, an exaggerated or unregulated immune response associated with excessive release of inflammatory cytokines, resulting in multi-organ damage and increased patient mortality [7]. In July 2021, the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group published the findings from a systematic review and meta-analysis of clinical trials, which included 10,930 patients, on the association between treatment with interleukin-6 (IL-6) antagonists and mortality in patients hospitalized for COVID-19 [8]. Meta-analysis showed that treatment with IL-6 antagonists, compared with usual care or placebo, resulted in a significantly lower 28-day all-cause mortality [8]. However, unlike dexamethasone, IL-6 Zonampanel and its receptor have a more specific role in the pathogenesis of COVID-19, which makes this cytokine a suitable candidate for targeted therapy for patients with the systemic effects of SARS-CoV-2 infection [9,10]. IL-6 is a proinflammatory cytokine produced by fibroblasts, lymphocytes, and monocyte/macrophages. In 2011, a humanized monoclonal antibody to the IL-6 receptor (IL-6R), tocilizumab (ACTEMRA) (Genentech, Inc., San Francisco, CA, USA) was the first humanized therapeutic monoclonal antibody to IL-6R to be approved by the US Food and Drug Administration (FDA) for the treatment MEKK12 of rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and Castlemans disease [11,12]. In August 2017, tocilizumab was approved to treat chimeric antigen receptor (CAR) T-cell therapy-induced cytokine release syndrome (CRS) [13]. Observational studies have shown that serum levels of IL-6 are correlated with the severity of the clinical signs and imaging findings in patients with COVID-19 [14]. Tocilizumab is an inhibitor of the IL-6 pathway, and controlled clinical trials have now supported its effects on patients with moderate and severe COVID-19. In a meta-analysis of eight randomized trials of patients hospitalized with COVID-19, all-cause mortality was lower among patients who received tocilizumab when compared with placebo or standard of care [15]. In June 2021, the US FDA granted emergency use authorization (EUA) for tocilizumab to treat hospitalized patients with moderate and severe COVID-19, based on the findings from two main clinical trials [16.17]. In April 2021, the results of the REMAP-CAP clinical trial (NCT02735707) were published [18]. This international, open-label, randomized trial included 803 patients with severe COVID-19 admitted to the intensive care unit (ICU), who required either respiratory or cardiovascular support [18]. Treatment with the IL-6 receptor (IL-6R) antagonists, tocilizumab and sarilumab, improved patient outcomes and survival [18]. However, all patients were enrolled within 24 hours of admission to the ICU, >80% were also treated with glucocorticoids, and 33% were also treated with remdesivir [18]. Intravenous remdesivir.